Guest Editor(s)

• Allan Tsung, MD

  Director of Department of Surgical Oncology, the Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.

  Website | E-mail

Special Issue Introduction

Special issue webinar: Surgical Resection for HCC: Insights into the Indications and the Prognosis

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and as the risk factors associated with HCC continue to the rise, so will the incidence of HCC. Treatment algorithms for patients with HCC are complex taking into account not only the extent of tumor burden but also the patient’s underlying liver dysfunction. Surgical resection remains a cornerstone of treatment for patients with HCC offering a potential chance for cure. Surgical resection is guided by both tumor burden and liver physiology where the surgeon must balance a complete tumor extirpation with leaving an adequate future liver remnant. Despite this, many patients are not surgical candidates for reasons including both patient and tumor factors. In addition, recurrence rates after resection remain high where up to seventy percent of patients experience disease recurrence in the liver at five years. In this edition of Hepatoma Research, we discuss the role of surgical resection as well as combination strategies for the treatment of patients with HCC.

The following topics are what we want to discuss in this special issue:
1.Criteria for Resection Beyond Barcelona Staging: Resecting the Aggressive Tumor.
2.Resection of the Diseased Liver and the Patient's Physiologic Reserve.
3.Management of the Future Liver Remnant: Strategies to Promote Hepatic Hypertrophy
4.Strategies of Tumor Downstaging for Resection
5.Resection versus Liver Transplant in the Well Compensated Liver
6.The Role of Minimally Invasive Surgery in the Treatment of HCC
7.Non-Resection Options for the Potentially Resectable HCC
8.Resection Strategy: Anatomic versus Non-Anatomic Resection
9.Surgical Treatment of Intra-Hepatic Recurrence
10.Adjuvant Treatment of HCC after Resection

Participants

1. Allan Tsung  Department of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
2. Timothy M. Pawlik  Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
3. Christopher J. Sonnendaym  Department of surgery, Michigan Medicine, Ann Arbor, MI, USA.
4. Will Chapman  Department of Surgery, Washington University in Saint Louis, Saint Louis, MO, USA.
5. Ho-Seong Han  Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
6. Shimul A. Shah Cincinnati Research on Outcomes and Safety in Surgery (CROSS), Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH., USA.
7. Adam C. Yopp Harold C. Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
8. Toru Beppu Department of Surgery, Yamaga City Medical Center, Kumamoto, Japan.
9. Nuh N. Rahbari Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
The list is arranged in no particular order and being updated. 

Submission Deadline

30 Mar 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=521
Submission Deadline: 30 Mar 2021
Contacts: Victoria Lee, Assistant Editor, editor_Victoria@hrjournal.net